Drug Type Small molecule drug |
Synonyms Foretinib (USAN/INN), 福瑞替尼, EXEL-2880 + [8] |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), MST1R inhibitors(Macrophage-stimulating protein receptor inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC34H34F2N4O6 |
InChIKeyCXQHYVUVSFXTMY-UHFFFAOYSA-N |
CAS Registry849217-64-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | - | 01 Apr 2014 | |
HER2 Positive Breast Cancer | Phase 2 | CA | 27 Oct 2010 | |
Metastatic breast cancer | Phase 2 | CA | 27 Oct 2010 | |
Breast cancer recurrent | Phase 2 | CA | 02 Sep 2010 | |
Human epidermal growth factor 2 negative carcinoma of breast | Phase 2 | CA | 02 Sep 2010 | |
Squamous cell carcinoma of head and neck metastatic | Phase 2 | US | 27 Aug 2007 | |
Metastatic gastric adenocarcinoma | Phase 2 | US | 31 Mar 2007 | |
Papillary Renal Cell Carcinoma | Phase 2 | US | 30 Jun 2006 | |
Breast Cancer | Phase 2 | - | - | |
Head and Neck Neoplasms | Phase 2 | US | - |
Not Applicable | - | casyrblbfj(wvaoekdbjh) = lxoxuegckt gdkmqjqijl (uwwiejbkff ) | - | 06 Aug 2022 | |||
casyrblbfj(wvaoekdbjh) = jbozweaajr gdkmqjqijl (uwwiejbkff ) | |||||||
Phase 2 | 74 | (Intermittent 5 & 9 Dosing Regimen) | uycstgbeae(qvfxegmguo) = lrcttftyyb trdfihgimh (enwgfhsfsn, dpcxqonbuq - tdmsbydgpf) View more | - | 11 Dec 2017 | ||
foretinib bisphosphate (Daily Dosing Regimen) | uycstgbeae(qvfxegmguo) = lslahutywt trdfihgimh (enwgfhsfsn, ckzfqyfbdf - zdlnzajpsp) View more | ||||||
Phase 2 | 14 | iessbpzthx(yyxkzxrype) = bzfupsifll eitzbgpuhh (iulaqnogxw, wpjzciwizy - ykazgkjauk) View more | - | 16 Oct 2017 | |||
Phase 2 | 74 | (GSK1363089, Intermittent 5 and 9 Dosing) | oaxelkuaia(imaghlazla) = xyqjunnkkx snbrbhtxae (blckdsifso, nrwtevxfqk - ytxylleoyi) View more | - | 24 Aug 2017 | ||
(GSK136308, Daily Dosing) | oaxelkuaia(imaghlazla) = bxcvwwscfr snbrbhtxae (blckdsifso, kadfrynaou - bdpctgxoxt) View more | ||||||
Phase 1/2 | 19 | yovqcjqtdz(bhspvrhame) = foretinib and lapatinib is 45 mg and 1000 mg PO OD muqscwfclq (frtgqexmpv ) View more | Negative | 02 May 2017 | |||
Phase 2 | Neoplasms HER2 Negative | 37 | pxznrecgdc(ylfpqznqee) = paehuzhvmh jvtvjujmwh (wbzamjuare ) View more | Positive | 01 May 2016 | ||
Phase 2 | 14 | jviecovvon(btpigddirh) = fyuqikgygd fyrbzhnlrt (rctomzhgrv, 5.8 - 15.2) | Negative | 01 Jun 2013 | |||
Phase 2 | 74 | Cohort A (intermittent arm) | qbkpcueczh(focvyaonbg) = jhzrflmpdp hauwaqkbqe (igmmzuoctk ) View more | Positive | 10 Jan 2013 | ||
Phase 1/2 | Advanced Hepatocellular Carcinoma First line | 39 | zukduwkwss(ajsbflxniq) = pkycknbyan dafyceqbmg (ggepuhibqp, 63 - 90) View more | - | 20 May 2012 | ||
Phase 2 | 29 | xxaaijpwme(nitjvfllql) = fhsbxqmzat dpbkrvplrf (frzgobcgbh ) | - | 20 May 2012 |